1.Relation of Cardiac Arrhythmias to Hypoxic Time and Lowest Oxygen Saturation in Patients with Obstructive Sleep Apnoea in an Asian Context: A Singapore Sleep Centre Study.
Adele Cw NG ; Wei Li NEO ; Mahalakshmi RANGABASHYAM ; Ying HAO ; Kah Leng HO ; Song Tar TOH
Annals of the Academy of Medicine, Singapore 2017;46(5):210-212
2.Clinical evaluation of an in-house human immunodeficiency virus (HIV) genotyping assay for the detection of drug resistance mutations in HIV-1 infected patients in Singapore.
Kuan Kiat CHEW ; Kah Ying NG ; Wei Xin KHONG ; Palvinder KAUR ; Joe Kwan YAP ; Arlene CHUA ; Mei Ting TAN ; Yin Ling KOH ; Koh Cheng THOON ; Yee Sin LEO ; Oon Tek NG
Annals of the Academy of Medicine, Singapore 2012;41(12):553-558
INTRODUCTIONHuman immunodeficiency virus type 1 (HIV-1) genotyping resistance test (GRT) is essential for monitoring HIV-1 drug resistance mutations (DRMs). High cost and HIV-1 genetic variability are challenges to assay availability in Singapore. An in-house Sanger sequencing-based GRT method was developed at the Communicable Disease Centre (CDC), Singapore's HIV national treatment reference centre for both subtype B and non-subtype B HIV-1.
MATERIALS AND METHODSThe in-house GRT sequenced the fi rst 99 codons of protease (PR) and 244 codons of reverse transcriptase (RT) in the pol gene. The results were compared with the Food and Drug Administration (FDA)-approved ViroSeq™ HIV-1 Genotyping System.
RESULTSSubtype assignment for the 46 samples were as follows: 31 (67.4%) CRF01_AE, 14 (30.5%) subtype B and 1 (2.1%) subtype C. All 46 samples had viral load of ≥500 copies/mL, and were successfully amplified by the in-house primer sets. Compared to the ViroSeq™ test, our in-house assay showed drug-resistance conferring codon concordance of 99.9% at PR and 98.9% at RT, and partial concordance of 0.1% at PR and 1.1% at RT. No discordant result was observed.
CONCLUSIONThe assay successfully identified DRMs in both subtype AE and B, making it suitable for the efficient treatment monitoring in genetically diverse population. At less than half of the running cost compared to the ViroSeq™ assay, the broadly sensitive in-house assay could serve as a useful addition to the currently limited HIV genotyping assay options for resource-limited settings, thereby enhancing the DRM surveillance and monitoring in the region.
Anti-Retroviral Agents ; pharmacology ; Drug Resistance, Viral ; genetics ; Genes, pol ; genetics ; Genotyping Techniques ; methods ; HIV Infections ; drug therapy ; virology ; HIV-1 ; drug effects ; genetics ; Humans ; Mutation ; Sequence Analysis, DNA ; methods ; Singapore
3.Cold chain time- and temperature-controlled transport of vaccines: a simulated experimental study
Chun Zheng NG ; Yen Loong LEAN ; Siang Fei YEOH ; Qi Ying LEAN ; Kah Seng LEE ; Amal Khalil SULEIMAN ; Kai Bin LIEW ; Yaman Walid KASSAB ; Yaser Mohammed AL-WORAFI ; Long Chiau MING
Clinical and Experimental Vaccine Research 2020;9(1):8-14
4.Guidance for the clinical management of infants born to mothers with suspected/confirmed COVID-19 in Singapore.
Kee Thai YEO ; Agnihotri BISWAS ; Selina Kah YING HO ; Juin Yee KONG ; Srabani BHARADWAJ ; Amutha CHINNADURAI ; Wai Yan YIP ; Nurli Fadhillah AB LATIFF ; Bin Huey QUEK ; Cheo Lian YEO ; Yvonne Peng MEI NG ; Kenny Teong TAI EE ; Mei Chien CHUA ; Woei Bing POON ; Zubair AMIN
Singapore medical journal 2022;63(9):489-496
In this paper, we provide guidance to clinicians who care for infants born to mothers with suspected/confirmed COVID-19 during this current pandemic. We reviewed available literature and international guidelines based on the following themes: delivery room management; infection control and prevention strategies; neonatal severe acute respiratory syndrome coronavirus 2 testing; breastfeeding and breastmilk feeding; rooming-in of mother-infant; respiratory support precautions; visiting procedures; de-isolation and discharge of infant; outpatient clinic attendance; transport of infant; and training of healthcare staff. This guidance for clinical care was proposed and contextualised for the local setting via consensus by members of this workgroup and was based on evidence available as of 31 July 2020, and may change as new evidence emerges.
Infant, Newborn
;
Pregnancy
;
Female
;
Humans
;
Mothers
;
COVID-19/epidemiology*
;
Singapore/epidemiology*
;
COVID-19 Testing
;
Pandemics/prevention & control*
;
Infectious Disease Transmission, Vertical/prevention & control*
;
Pregnancy Complications, Infectious/prevention & control*